Medicine and Dentistry
Abdominal Pain
6%
Acute Hemorrhagic Pancreatitis
9%
Acute Liver Failure
62%
Acute on Chronic Liver Failure
27%
Acute Pancreatitis
7%
Adenocarcinoma
11%
Adverse Event
5%
Alcohol Liver Disease
28%
Ammonium
5%
Anastrozole
9%
APC
32%
Bacterial Infection
18%
Bilirubin
13%
Biological Product
9%
Black Population
9%
Bleeding
11%
Brain Imaging
9%
CA-125
9%
Cancer Diagnosis
9%
Cancer Incidence
15%
Cancer Staging
15%
Carcinoma Cell
9%
Carotid Atherosclerosis
9%
Central Nervous System
9%
Chronic Liver Disease
7%
Clinical Feature
9%
Coagulopathy
13%
Cohort Effect
16%
Colitis
9%
Colonoscopy
5%
Colorectal Cancer
11%
Cost-Effectiveness Analysis
9%
COVID-19
11%
Decompensated Liver Cirrhosis
11%
Disease
41%
Disease Severity
9%
Drug Therapy
21%
Drug Use
9%
Dysbiosis
9%
Early Diagnosis
6%
Emricasan
27%
Endoscopy
7%
Epileptic Absence
8%
Epileptic Seizure
9%
Epstein Barr Virus
9%
Esophagus
9%
Ethnic Disparity
9%
Ethnic Group
5%
Fatty Liver
18%
Fibrogenesis
9%
Fibrosis
12%
Fistula
9%
Gallbladder Cancer
9%
Gastroesophageal Reflux
9%
Gastrointestinal Distress
9%
Gastroplasty
9%
Gut
6%
Gut Microbiome
9%
Gut Microbiota
19%
Headache
9%
Health Care Cost
10%
Hepatic Encephalopathy
20%
Hepatitis B
8%
Hepatitis B Virus
18%
Hepatitis C
6%
Hepatitis E Virus
9%
Hepatocellular Carcinoma
49%
Hepatology
12%
Hepatorenal Syndrome
9%
Hypertriglyceridemia
9%
Identified Patient
9%
Infection
29%
Ledipasvir Plus Sofosbuvir
9%
Liver Cirrhosis
100%
Liver Disease
12%
Liver Failure
13%
Liver Fibrosis
9%
Liver Function
9%
Liver Graft
16%
Liver Injury
20%
Liver Transplantation
53%
Malignant Neoplasm
17%
MALT Lymphoma
9%
Meningitis
9%
Meta-Analysis
9%
Metabolome
9%
Metastatic Carcinoma
5%
Microbiome
11%
Model For End Stage Liver Disease Score
15%
Model for End-Stage Liver Disease
6%
Mortality Rate
12%
Neoplasm
19%
Neuroendocrine Tumor
18%
Non-Alcoholic Fatty Liver Disease
13%
Nonalcoholic Fatty Liver
59%
Organ Transplantation
9%
Parenchyma
9%
Patient with Ulcerative Colitis
9%
Placebo
24%
Plasmapheresis
5%
Portal Hypertension
24%
Prevalence
24%
Racial Disparity
18%
Recidivism
9%
Recurrent Disease
9%
Retrospective Study
9%
Right Atrium
6%
Signet Ring Cell Carcinoma
6%
Steatosis
6%
Stomach Cancer
9%
Stomach Mucosa
9%
Symptom
11%
Therapeutic Modality
9%
Thromboelastography
9%
Transjugular Intrahepatic Portosystemic Shunt
9%
Transplantation
18%
Transverse Colon
9%
Tumor Antigen
9%
Tumor Thrombus
9%
Ulcerative Colitis
9%
Upper Gastrointestinal Bleeding
9%
Venous Pressure
9%
Keyphrases
AASLD
9%
Acetaminophen-induced Hepatotoxicity
9%
Acute Liver Failure
46%
Acute Necrotizing Pancreatitis
9%
Acute Variceal Bleeding
9%
Acute-on-chronic
9%
Acute-on-chronic Liver Failure
9%
Adenocarcinoma
9%
African American
7%
African American Patients
9%
Alcoholic Cirrhosis
9%
Alcoholic Liver Disease
9%
Anti-hepatic Fibrosis
9%
Biologic Era
9%
Black African
9%
Cancer Incidence
11%
Cancer Management
9%
Carbohydrate Antigen 125 (CA125)
9%
Carotid Artery Atherosclerosis
9%
Chronic Liver Disease
6%
Cirrhosis
33%
Cirrhotic Patients
10%
Clinical Application
9%
Clinical Evolution
9%
Coagulopathy
11%
Colitis
9%
Comparative Analysis
12%
Concentration Reduction
9%
Confidence Interval
14%
Congestive Hepatopathy
6%
Cost-effectiveness Analysis
9%
COVID-19
9%
Daclatasvir
9%
Deceased Donor
9%
Disease Mechanisms
18%
Disease Severity
9%
Donor Potential
9%
Double Lumen
9%
Dysbiosis
10%
Early-onset Colorectal Cancer (EOCRC)
9%
Emerging Pharmacotherapy
9%
Emricasan
9%
Epstein-Barr Virus
9%
Esophagopleural Fistula
9%
Ethnic Groups
5%
Failure Mechanism
18%
Fatty Liver Disease
9%
Financial Burden
9%
Gallbladder Cancer
9%
Gastrointestinal Diseases
9%
Global Action
9%
Graft Steatosis
6%
Gut Microbiome
9%
Gut Microbiota
5%
Gut Microbiota Modulation
9%
HBV Reactivation
6%
HCV Infection
9%
HCV Reactivation
9%
Henoch-Schönlein Purpura
9%
Hepatic Encephalopathy
9%
Hepatic Failure
11%
Hepatic Venous Pressure Gradient
9%
Hepatitis
9%
Hepatitis B
6%
Hepatocellular Carcinoma
39%
Hepatocellular Carcinoma Surveillance
9%
Hepatotoxicity
9%
Human Genome
9%
Hypertriglyceridemia
9%
IDN-6556
9%
IFN-α2b
7%
Immune System
9%
Immunocompetent Individual
9%
Improved Outcomes
11%
In-hospital Mortality
9%
Incidence Rate
9%
Latino Patients
9%
Ledipasvir
9%
Length of Stay
9%
Liver
20%
Liver Failure Acute
9%
Liver Transplantation
42%
Locally Advanced Gastric Cancer
9%
Management Modalities
10%
Meta-analysis
9%
Metabolic-associated Fatty Liver Disease (MAFLD)
6%
Metabolism
9%
Microbiota
9%
Mortality Burden
9%
Mortality Rate
9%
Multisystem Involvement
18%
National Inpatient Sample
9%
Neuroendocrine Tumor
9%
Non-alcoholic Fatty Liver Disease (NAFLD)
27%
Non-Hispanic White
9%
Nonalcoholic Steatohepatitis
9%
Noninvasive Risk Assessment Tests
9%
Nutritional Modulation
9%
Online Patient Education
9%
Organ Procurement
9%
Organ Transplantation
9%
Ornithine Phenylacetate
9%
Pathogen Colonization
9%
Peginterferon
9%
People of Color
6%
Plasma Ammonia
9%
Plasmapheresis
6%
Poor Clinical Outcomes
9%
Portal Hypertension
9%
Portal Hypertensive
7%
Post-acute
9%
Potential Donor
9%
Preoperative Chemotherapy
9%
Primary Biliary Cholangitis
9%
Proof of Concept Study
9%
Quality-adjusted Life Years
5%
Racial Disparities
18%
Rate Ratio
6%
Re-suturing
9%
Reading Grade Level
9%
Reading Material
6%
Rectal Neuroendocrine Tumor
9%
Ribavirin
9%
Right Atrial Tumor
9%
Scoping Review
9%
Score-based Modeling
9%
Severe Alcoholic Hepatitis
9%
Severe Portal Hypertension
9%
Single-center Experience
9%
Solid Dispersion Tablet
9%
Subnational Analysis
9%
Superior Performance
9%
Syphilitic Hepatitis
9%
Systems Education
9%
Terlipressin
9%
Therapeutic Modalities
9%
Thromboelastography
9%
Tolerance Development
9%
Transfusion
5%
Transplant Center
5%
Transplantation
10%
Tumor
5%
Unintentional Use
9%
United States
12%
Upfront Surgery
7%
Viscoelastic Testing
9%
Weight Recidivism
9%
World Journal of Hepatology
9%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Liver Failure
35%
Acute on Chronic Liver Failure
18%
Adverse Event
6%
Alcohol Liver Disease
12%
Ammonium
9%
Anaphylactoid Purpura
9%
Antilipemic Agent
9%
Antivirus Agent
6%
APC
9%
Bacterial Infection
18%
Bilirubin
11%
Biological Product
9%
Bleeding
18%
Caspase Inhibitor
5%
Chemotherapy
9%
Clinical Feature
9%
Clinical Trial
8%
Crohn's Disease
9%
Daclatasvir
9%
Decompensated Liver Cirrhosis
22%
Disease
29%
Disease Course
8%
Emricasan
37%
End Stage Liver Disease
19%
Epileptic Absence
5%
Ethanol
11%
Fatty Liver
17%
Fibrosis
21%
Gallbladder Cancer
9%
Hepatic Encephalopathy
16%
Hepatitis B
15%
Hepatitis B Virus
18%
Hepatitis C
9%
Hepatitis E
9%
Hepatitis E Virus
9%
Hepatotoxicity
23%
Hospital Mortality
5%
Infection
47%
Inflammation
9%
Inflammatory Bowel Disease
9%
Interferon
9%
Intestine Flora
11%
Ledipasvir Plus Sofosbuvir
9%
Liver Cell Carcinoma
24%
Liver Cirrhosis
95%
Liver Disease
5%
Liver Failure
6%
Liver Fibrosis
11%
Liver Injury
21%
Malignant Neoplasm
17%
Microbiome
16%
Mortality Rate
12%
Neoplasm
9%
Nonalcoholic Fatty Liver
50%
Obeticholic Acid
9%
Ornithine Phenylacetate
18%
Paracetamol
18%
Pathophysiology
6%
Peginterferon
9%
Pharmacodynamics
9%
Pharmacokinetics
9%
Pharmacotherapy
9%
Placebo
40%
Portal Hypertension
18%
Prevalence
17%
Ribavirin
13%
Rifaximin
9%
Saroglitazar
9%
Scar Formation
11%
Stomach Cancer
9%
Systemic Treatment
9%
Tablet
9%
Terlipressin
9%
Toxic Injury
7%
Ulcerative Colitis
9%
Upper Gastrointestinal Bleeding
9%
Viral Clearance
9%
Virus Hepatitis
5%
Vitamin D
9%